Compare IHD & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHD | APYX |
|---|---|---|
| Founded | 2011 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.9M | 122.2M |
| IPO Year | N/A | 1995 |
| Metric | IHD | APYX |
|---|---|---|
| Price | $7.54 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 69.7K | ★ 114.6K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | ★ 19.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.93 |
| Revenue Next Year | N/A | $11.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.93 | $1.70 |
| 52 Week High | $8.14 | $5.08 |
| Indicator | IHD | APYX |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 40.26 |
| Support Level | $7.46 | $2.82 |
| Resistance Level | $7.64 | $3.29 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 30.97 | 52.62 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.